First Sickle Cell Patient Dosed in Phase 2a of IMR-687 | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

First Sickle Cell Patient Dosed in Phase 2a of IMR-687


This morning, Imara Inc. announced that it has dosed the first patient in its Phase 2a clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IMR-687 in adult patients with sickle cell disease (SCD).

In May, IMR-687 was granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA), the first SCD product candidate to receive the label. The drug is being developed as a highly-potent oral therapy for once-daily dosing with the intention of addressing both the underlying red and white blood cell pathologies associated with the condition.

SCD is a severe, hereditary variation of anemia in which a mutated form of hemoglobin distorts the red blood cells at low oxygen levels into crescent-shaped cells that resemble a sickle. “IMR-687 is being rapidly advanced, as Imara is dosing the first eligible patient less than 2 years from the launch of the company.

https://www.onescdvoice.com/wp-content/uploads/2018/02/imara.png